The Patent Finder

Savient Pharmaceuticals, Inc.

Also on record
Records under this name other than patents Savient Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Savient Pharmaceuticals, Inc.

PatentTitleStatus Expires Confidence
US 8,148,123Methods for Lowering Elevated Uric Acid Levels Using Intravenous Injections of Peg-Uricase
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 9,534,013Purification of Proteins With Cationic Surfactant
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,377,454Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,139,399Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,823,727Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,598,767Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,639,927Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,982,670Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 12,188,927Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 7,811,800Variant Form of Urate Oxidase and Use Thereof
Formerly held
Term ended
Term ended Apr 11, 2026 · High confidence
Term endedTerm ended Apr 11, 2026High confidence
10 of 75 patents shown.
Pro members see all 75.
Pro members: see all 75 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited